List view / Grid view

News

Lonza and Biowa sign license agreements with FivePrime Therapeutics

13 June 2012 | By

Five Prime Therapeutics, Inc. (“FivePrime”) has entered into research and commercial agreements with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime’s oncology pipeline.